Novozymes announces sensational new antibiotic discovery  

Denmark's Novozymes has discovered a new antimicrobial peptide (AMP) active against multi-resistant bacteria that pose a threat to global health

Denmark's Novozymes has discovered a new antibiotic against multi-resistant bacteria that pose a threat to global health. The antimicrobial peptide (AMP) plectasin promises to deliver effective treatment for otherwise incurable diseases such as pneumonia, septicaemia and meningitis. Plectasin was discovered in a black mushroom, Pseudoplectania nigrella, which grows in coniferous forests in northern Europe.

Novozymes will publish the epoch making discovery today in the world renowned scientific journal Nature. "The substance is commercially interesting and can be produced in very large quantities and purity", the article states.

So far plectasin has been tested on mice. A single dose enabled 9 out of 10 mice to survive an applied infection which otherwise would have been fatal in all cases. The news was published by professional journal Ingeniøren (The Engineer).

Novozymes is the biotech-based world leader in enzymes and microorganisms. Headquartered in Bagsværd on the outskirts of Copenhagen, the company employs 4,000 people, half of whom are stationed in Denmark. Novozymes' 700 products are a key factor in the production of thousands of products used in everyday life. The company's B shares are listed on Copenhagen Stock Exchange.

Link > Novozymes 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×